GSK'S Nucala (mepolizumab), is listed as an add-on treatment for adults 18 with chronic rhinosinusitis with nasal polyps (CRSwNP) that is severe, eosinophilic and recurrent post-surgery.
Nucala is the first monoclonal antibody to be PBS-subsidised for CRSwNP.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Apr 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Apr 23
Warning: Undefined variable $o_shortcode_atts in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1263
Warning: Undefined variable $output in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1266
